Evidence map›Paper›PMID 31042161›Full record

ArticleThe Journal of clinical investigation2019

Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.

Julia Rühl, Carmen Citterio, Christine Engelmann, Tracey Haigh, Andrzej Dzionek, Johannes Dreyer, Rajiv Khanna, Graham S Taylor, Joanna B Wilson, Carol S Leung and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Increasing intrinsic protein disorder improves CD8+ immunogenicity for a SARS CoV2 vaccine candidate antigen.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Julia RühlViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Carmen CitterioViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Christine EngelmannViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Tracey HaighCancer Immunology and Immunotherapy Centre, University of Birmingham, Birmingham, United Kingdom.
Andrzej DzionekMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Johannes DreyerInstitute for Pathology, Unfallkrankenhaus Berlin, Berlin, Germany.
Rajiv KhannaQIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Graham S TaylorCancer Immunology and Immunotherapy Centre, University of Birmingham, Birmingham, United Kingdom.
Joanna B WilsonCollege of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Carol S LeungUniversity of Oxford, Nuffield Department of Medicine, Ludwig Institute for Cancer Research, Oxford, United Kingdom.
Christian MünzViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
University of Zurich · CHUniversity of Birmingham · GBLudwig Cancer Research · GBMiltenyi Biotec (Germany) · DEQIMR Berghofer Medical Research Institute · AUUnfallkrankenhaus Berlin · DEUniversity of Glasgow · GB

Funding

Cancer Research UK 13174
6 · The paper itself

Abstract

The Epstein-Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available. We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EBV (EBNA1), either targeted to the DEC205 receptor on DCs or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector, improved priming of antigen-specific CD4+ T cell help. This help supported the expansion and maintenance of EBNA1-specific CD8+ T cells that are most efficiently primed by recombinant adenoviruses that encode EBNA1. These combined CD4+ and CD8+ T cell responses protected against EBNA1-expressing T and B cell lymphomas, including lymphoproliferations that emerged spontaneously after EBNA1 expression. In particular, the heterologous EBNA1-expressing adenovirus, boosted by EBNA1-encoding MVA vaccination, demonstrated protection as a prophylactic and therapeutic treatment for the respective lymphoma challenges. Our study shows that such heterologous prime-boost vaccinations against EBV-associated malignancies as well as symptomatic primary EBV infection should be further explored for clinical development.

Indexed as

AnimalsCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensGenetic VectorsHEK293 CellsHerpesvirus 4, HumanHumansImmunoglobulin GInterferon-gammaLeukocytes, MononuclearLymphomaMiceCancer VaccinesEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensImmunoglobulin GInterferon-gammaImmunologyLymphomas

Identifiers

PMID31042161
PMCPMC6486346
OpenAlexW2921300524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.